search
Back to results

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

Primary Purpose

Obesity

Status
Completed
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
ZGN-433
Sponsored by
Zafgen, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obese, Obesity, Overweight

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Obese, otherwise healthy females
  • Post menopausal or infertile
  • Weight ≥ 50 kg
  • BMI ≥ 32 and ≤ 45 kg/m2

Exclusion Criteria:

  • Use of weight loss agents in the past month
  • History of eating disorder
  • History of diabetes or other endocrine disorder
  • History of gastric bypass
  • Current smokers
  • Unstable body weight during the past 3 months

Sites / Locations

  • Q-Pharm Clinics, Royal Brisbane and Women's Hospital
  • Nucleus Network

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ZGN-433

Normal Saline

Arm Description

Outcomes

Primary Outcome Measures

Measures of the safety and tolerability of ZGN-433 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, heart rhythm, and laboratory tests.

Secondary Outcome Measures

Weight

Full Information

First Posted
December 7, 2009
Last Updated
January 9, 2012
Sponsor
Zafgen, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01028261
Brief Title
Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers
Official Title
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZGN-433 in Obese Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zafgen, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well tolerated in obese female subjects. The study will also provide information on how much ZGN-433 gets into the blood, how long does it stay in the body, and how it affects other biological markers.
Detailed Description
This protocol is designed to test the safety and preliminary efficacy of a drug called ZGN-433. It is to be tested for its ability to reduce weight in severely obese female subjects who are post menopausal or infertile.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obese, Obesity, Overweight

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ZGN-433
Arm Type
Experimental
Arm Title
Normal Saline
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
ZGN-433
Other Intervention Name(s)
Beloranib hemioxalate
Intervention Description
Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
Primary Outcome Measure Information:
Title
Measures of the safety and tolerability of ZGN-433 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, heart rhythm, and laboratory tests.
Time Frame
Approximately 2 months
Secondary Outcome Measure Information:
Title
Weight
Time Frame
Approximately 2 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Obese, otherwise healthy females Post menopausal or infertile Weight ≥ 50 kg BMI ≥ 32 and ≤ 45 kg/m2 Exclusion Criteria: Use of weight loss agents in the past month History of eating disorder History of diabetes or other endocrine disorder History of gastric bypass Current smokers Unstable body weight during the past 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James E Vath, PhD
Organizational Affiliation
Zafgen, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Q-Pharm Clinics, Royal Brisbane and Women's Hospital
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4006
Country
Australia
Facility Name
Nucleus Network
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

We'll reach out to this number within 24 hrs